FOXO

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

Retrieved on: 
Wednesday, February 14, 2024
Engineering, Unitary state, Intelligence, OTC, Government, Federation, FOXO, Interim, Knowledge, Research, Partnership

Mark White, Interim CEO of FOXO Technologies, “We could not be more excited to advance this potential merger transaction with M2i, whose board and management team bring extensive experience, knowledge, resources and relationships around the world in developing efficient supply chains and securing mineral reserves to help protect the national interests of the U.S.

Key Points: 
  • Mark White, Interim CEO of FOXO Technologies, “We could not be more excited to advance this potential merger transaction with M2i, whose board and management team bring extensive experience, knowledge, resources and relationships around the world in developing efficient supply chains and securing mineral reserves to help protect the national interests of the U.S.
  • Importantly, M2i’s management has impressive track records driving significant value for shareholders, including M2i’s Executive Chairman Doug Cole, who orchestrated a successful turnaround of American Battery Metals Corporation.
  • M2i aims to build a comprehensive global supply chain for critical minerals, in collaboration with the U.S. Federal Government and international partners, addressing the global shortage outside China and seizing the economic opportunity to meet increasing demand.
  • For more information on M2i Global, Inc., please visit: https://www.m2i.global

FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors

Retrieved on: 
Thursday, January 25, 2024
Software, Biotechnology, Health, Artificial Intelligence, Health Technology, Technology, Genetics, Health Insurance, Failure, Tulane University, Interim, Prudential Securities, FOXO, Business studies

FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced the appointment of Francis Colt deWolf to the Company’s Board of Directors.

Key Points: 
  • FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced the appointment of Francis Colt deWolf to the Company’s Board of Directors.
  • Prior to founding Colt Capital LLC, Mr. deWolf was a Senior Vice President at Oppenheimer and Company, where he oversaw a variety of financing activities.
  • “I could not be more delighted to welcome a capital markets executive of Francis’ stature to our board of directors,” stated Mark White, Interim CEO of FOXO Technologies.
  • The Company believes that the appointment of Mr. deWolf to the Board of Directors will resolve the issue of noncompliance.

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

Retrieved on: 
Monday, January 22, 2024
Technology, Professional Services, Health, Biometrics, Health Technology, Apps, Applications, Data Analytics, Software, Artificial Intelligence, Genetics, Fitness & Nutrition, Saliva, Algorithm, Interim, FOXO, Medical device

Mark White, Interim CEO of FOXO Technologies, stated, “Formalization of this agreement is an important milestone as we advance our new direct-to-consumer offering.

Key Points: 
  • Mark White, Interim CEO of FOXO Technologies, stated, “Formalization of this agreement is an important milestone as we advance our new direct-to-consumer offering.
  • By leveraging our epigenetic data, genetic insight and growing patent estate, with KR8’s AI-driven analytic software and proprietary algorithms, we aim to provide the most robust direct-to-consumer health and wellness app in the industry.
  • Since initially announcing the collaboration, we have made tremendous progress and are well ahead of schedule with our planned commercial launch.
  • We could not be more excited about the outlook for VITHAR™ and look forward to providing further updates.”

FOXO Technologies On Track to Commence Commercial Rollout of VITHAR™ AI Health Coach in Early 2024

Retrieved on: 
Friday, December 1, 2023
Data Management, Other Technology, Technology, Artificial Intelligence, Software, Algorithm, DTC, Health, Social media, Interim, NYSE, FOXO, Mobile phone

FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a business update on the planned commercial rollout of its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach.

Key Points: 
  • FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a business update on the planned commercial rollout of its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach.
  • Mark White, Interim CEO of FOXO Technologies, stated, “We are making rapid progress with the planned rollout of our VITHAR™ AI Health Coach and I am pleased to report the commercial launch is on track for early 2024.
  • We believe the new direct-to-consumer offering will provide users with unprecedented health insights and coaching by leveraging the Company’s proprietary epigenetic data and algorithms.
  • Moreover, we expect to maintain a lean operating infrastructure, which we believe will allow us to rapidly scale the business and drive profitability following the commercial launch of the VITHAR AI Health Coach.”

FOXO Technologies Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q

Retrieved on: 
Wednesday, November 29, 2023
Health, Technology, Health Technology, Genetics, Software, Artificial Intelligence, Biotechnology, NYSE American, NYSE, FOXO, Form 10-Q, Annual report, Form, Exchange, Medical device

The non-compliance results from the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Delinquent Report”) by the filing due date of November 20, 2023 (the “Filing Delinquency”).

Key Points: 
  • The non-compliance results from the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Delinquent Report”) by the filing due date of November 20, 2023 (the “Filing Delinquency”).
  • If the Company fails to file the Form 10-Q during the Initial Cure Period, the Exchange may, in its sole discretion, provide an additional six-month cure period (the “Additional Cure Period”).
  • The Company can regain compliance with the Exchange’s continued listing standards at any time during the Initial Cure Period or Additional Cure Period, as applicable, by filing the Form 10-Q and any subsequent delayed filings with the SEC.
  • The Company filed its Annual Report on Form 10-K with the SEC on March 30, 2023, and expects to file its Form 10-Q as soon as practicable.

Iorio Altamirano LLP Encourages Investors to File FINRA Arbitration Claims Over GWG L Bonds Losses

Retrieved on: 
Tuesday, November 21, 2023
Legal, Professional Services, Wind, GWG, Richard L. Bond, FINRA, Bankruptcy, Financial adviser, Security (finance), FOXO

National investment loss lawyers Iorio Altamirano LLP continue to investigate broker-dealers that sold GWG L Bonds to retail investors.

Key Points: 
  • National investment loss lawyers Iorio Altamirano LLP continue to investigate broker-dealers that sold GWG L Bonds to retail investors.
  • Iorio Altamirano LLP represents dozens of GWG L Bond investors across the country and encourages investors who are taking a “wait and see approach” to act now.
  • In light of recent developments in the GWG bankruptcy proceeding and FINRA Arbitration wins for GWG L Bond investors, there is no reason for anyone with meritorious claims to wait to initiate a FINRA arbitration proceeding.
  • Iorio Altamirano LLP was at the forefront of the investigation into the GWG L Bonds starting in late 2021 and has already helped investors recover $1.5 million in losses.

FOXO Technologies Provides Reminder for Webinar to be Held Today, November 10th at 10 AM Eastern Time, to Unveil VITHAR™ AI Health Coach

Retrieved on: 
Friday, November 10, 2023
Health, Technology, Software, General Health, Research, Artificial Intelligence, Science, Algorithm, DTC, API, NYSE, Ecosystem, FOXO, Medical device

FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a reminder that it will host a webinar on Friday, November 10, 2023, at 10 AM Eastern Time, which will be available on the Company’s website at https://foxotechnologies.com/ .

Key Points: 
  • FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a reminder that it will host a webinar on Friday, November 10, 2023, at 10 AM Eastern Time, which will be available on the Company’s website at https://foxotechnologies.com/ .
  • The Company plans to unveil its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which is designed to intake health data from available APIs already on the user's mobile and wearable devices, and combine this data with the individual’s epigenetic data through the Company’s proprietary epigenetic data and algorithms.
  • The new DTC offering will leverage KR8’s AI ecosystem to provide users with actionable health insights and coaching.

FOXO Technologies to Unveil VITHAR™ AI Health Coach; Schedules Webinar for Friday, November 10th at 10 AM Eastern Time

Retrieved on: 
Wednesday, November 8, 2023
Software, Other Health, General Health, Mobile, Wireless, Biometrics, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Health Technology, Fitness & Nutrition, Biotechnology, Health, FOXO, Longevity, Algorithm, Interim, DTC, Risk, NYSE, Ecosystem, DNA, API, Mobile phone

The Company plans to unveil its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which is designed to intake health data from available APIs already on the user's mobile and wearable devices, and combine this data with the individual’s epigenetic data through the Company’s proprietary epigenetic data and algorithms.

Key Points: 
  • The Company plans to unveil its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which is designed to intake health data from available APIs already on the user's mobile and wearable devices, and combine this data with the individual’s epigenetic data through the Company’s proprietary epigenetic data and algorithms.
  • The new DTC offering will leverage KR8’s AI ecosystem to provide users with actionable health insights and coaching.
  • Mark White, Interim CEO of FOXO Technologies, stated, “The FOXO and KR8 teams have been working tirelessly to develop the new VITHAR™ AI Health Coach.
  • We look forward to unveiling the full offering in our upcoming webinar.”

FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split

Retrieved on: 
Tuesday, November 7, 2023
Science, Software, Biotechnology, Research, Pharmaceutical, Health, Technology, Genetics, FOXO, Common stock, Interim, NYSE American, NYSE, Partnership

FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it expects its Class A common stock (the “Common Stock”) to resume trading today, November 7, 2023, in connection with a 1-for-10 reverse stock split of its issued and outstanding shares of Common Stock to regain compliance with the continued listing requirements, as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").

Key Points: 
  • FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it expects its Class A common stock (the “Common Stock”) to resume trading today, November 7, 2023, in connection with a 1-for-10 reverse stock split of its issued and outstanding shares of Common Stock to regain compliance with the continued listing requirements, as set forth in Section 1003(f)(v) of the NYSE American Company Guide ("Company Guide").
  • The Company’s Common Stock will continue to trade on NYSE American under the symbol "FOXO" and will begin trading on a split-adjusted basis when the market opens today, November 7, 2023.
  • The new product offering, designed to maximize value for our stockholders, leverages our epigenetic data and analytics through a commercial partnership with KR8.ai.
  • We are delighted to announce that trading is expected to resume on the NYSE American following the reverse split, and we look forward to announcing a number of key strategic developments on our overall strategy in the days and weeks ahead.”

FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company’s Epigenetic Data with the Power of AI

Retrieved on: 
Monday, October 30, 2023
Health, Communications, Social Media, Technology, Software, General Health, Artificial Intelligence, Intelligence, Social media, NYSE, Genetics, FOXO, Partnership, Interim, Saliva, Gene, Algorithm, AI, Health Resources and Services Administration, Medical device

Mark White, Interim CEO of FOXO Technologies, stated, “We are excited to formally unveil plans for our new direct-to-consumer offering.

Key Points: 
  • Mark White, Interim CEO of FOXO Technologies, stated, “We are excited to formally unveil plans for our new direct-to-consumer offering.
  • This strategy is designed to leverage our epigenetic data and analytics, which we believe reflects our core strength and includes some of the most advanced capabilities in the industry.
  • Fully unlocking the value of epigenetic data has been a challenge due to complexities in data processing and interpretation.
  • We look forward to not just using AI as a tool, but as a companion in people's health journey.”